靶向药物治疗的出现极大改变了晚期非小细胞肺癌（NSCLC）的治疗格局，但靶向药物抗癌治疗的心脏副作用严重影响NSCLC的预后，已成为第二大治疗手段。癌症患者的死亡原因。因此，早期识别靶向药物的心脏毒副作用对于心血管疾病的预防和治疗至关重要。讨论新型靶向药物表皮生长因子受体抑制剂可能引起的心脏毒性副作用，包括血栓栓塞事件、心力衰竭、心肌病、心律失常和高血压等，并总结其各自心血管不良反应的机制，以提供有益的建议。用于晚期肺癌患者的心脏管理，以最大限度地提高肺癌幸存者的治疗效果。临床医生需要平衡恶性肿瘤靶向治疗与药物引起的心脏毒性之间的风险收益比，通过心电图、心脏影像、生物标志物等评估和监测TKIs引起的心脏毒性，尽快排除易感危险因素尽可能为临床使用该类药物治疗恶性肿瘤提供参考。Copyright © 2024 Wang, Qiu, Deng, Wan.

The advent of targeted drug therapy has greatly changed the treatment landscape of advanced non-small cell lung cancer(NSCLC), but the cardioxic side effects of targeted drug anti-cancer therapy seriously affect the prognosis of NSCLC, and it has become the second leading cause of death in cancer patients. Therefore, early identification of the cardiotoxic side effects of targeted drugs is crucial for the prevention and treatment of cardiovascular diseases. The cardiotoxic side effects that may be caused by novel targeted drugs epidermal growth factor receptor inhibitors, including thromboembolic events, heart failure, cardiomyopathy, arrhythmia and hypertension, are discussed, and the mechanisms of their respective adverse cardiovascular reactions are summarized, to provide useful recommendations for cardiac management of patients with advanced lung cancer to maximize treatment outcomes for lung cancer survivors. Clinicians need to balance the risk-benefit ratio between targeted therapy for malignant tumors and drug-induced cardiotoxicity, and evaluate and monitor TKIs-induced cardiotoxicity through electrocardiogram, cardiac imaging, biomarkers, etc., so as to remove the susceptibility risk factors as soon as possible and provide a reference for the clinical use of such drugs in the treatment of malignant tumors.Copyright © 2024 Wang, Qiu, Deng and Wan.